Spatial patterns of glioblastoma failure related to contouring strategy of adjuvant radiotherapy (RTOG vs. EORTC target volumes approach): clinical trial introduction

Česká verzia

Authors: R. Hejnová ¹; A. Holešovská ¹; P. Pospíšil ^2,3; R. Lakomý ^4,5; L. Hynková ^2,3; I. Selingerová ⁶; R. Belanová ^7,8; M. Standara ⁷; R. Jančálek ^9,10; M. Smrčka ¹¹; P. Fadrus ¹¹; K. Múčková ¹²; M. Hendrych ¹³; T. Chodúr ¹⁴; K. Šiff Elová ¹⁴; J. Šána ^4,5,12; T. Prochazka ²; O. Slabý ^4,5,12; P. Šlampa ^2,3; T. Kazda ^2,3,6
Authors place of work: Oddělení klinických hodnocení, MOÚ, Brno ¹; Klinika radiační onkologie MOÚ, Brno ²; Klinika radiační onkologie LF MU, Brno ³; Klinika komplexní onkologické péče MOÚ, Brno ⁴; Klinika komplexní onkologické péče LF MU, Brno ⁵; Výzkumné centrum aplikované molekulární onkologie (RECAMO), MOÚ, Brno ⁶; Oddělení radiologie, MOÚ, Brno ⁷; LF MU, Brno ⁸; Neurochirurgická klinika FN u sv. Anny v Brně ⁹; Neurochirurgická klinika LF MU a FN U sv. Anny v Brně ¹⁰; Neurochirurgická klinika, LF MU a FN Brno ¹¹; Ústav patologie LF MU a FN Brno ¹²; I. ústav patologie LF MU a FN u sv. Anny v Brně ¹³; Úsek klinické psychologie, MOÚ, Brno ¹⁴
Published in the journal: Klin Onkol 2020; 33(Suppl 1): 20-26
Category: Review
doi: https://doi.org/10.14735/amko2020S20

Summary

Background: Glioblastoma represents the most common and the most aggressive primary brain tumor in adults. Radiotherapy is indicated in almost all patients suffering with this disease. The importance of valid contouring (target volume definition) in radiotherapy of glioblastomas is currently increasing. The two basic contouring approaches in glioblastoma are the „American“ approach of the Radiation Therapy Oncology Group (RTOG contouring approach defining two target volumes) and the „European“ approach of the European Organization for Research and Treatment of Cancer (EORTC contouring approach with one target volume). Both mentioned approaches are considered standard of radiotherapy care. In daily radiotherapy practice, a specific contouring procedure is often chosen also according to the convention and tradition of the pertinent workplace. An important parameter in assessing the approach to contouring in radiotherapy is the evaluation of patterns of failure (PoF, spatial evaluation of subsequent relapses).

Purpose: The GlioART, academic investigator initiated clinical study, compares the RTOG and EORTC approaches in a prospective setup, taking into account all parameters necessary for valid evaluation of progressions – definition of relapses, MR specification demonstrating progression, planned radiotherapy technique, glioblastoma molecular biological characteristics, resection extent and localization of the original glioblastoma. The aim of this paper is to present the GlioART study and to discuss the associated topics associated with defining the target volumes in radiotherapy.

Conclusion: The results of the GlioART trial may define recommendations influencing daily clinical practice in glioblastoma radiotherapy.

Keywords:

radiotherapy – glioblastoma – contouring – patterns of failure – GlioART

Zdroje

1. Cabrera AR, Kirkpatrick JP, Fiveash JB et al. Radiation Therapy for Glioblastoma: An ASTRO Evidence-Based Clinical Practice Guideline Conflict of Interest Disclosure Statement. [online]. Available from: https: //www.academia.edu/33797331/SUPPLEMENTAL_MATERIAL_Radiation_Therapy_for_Glioblastoma_An_ASTRO_Evidence-Based_Clinical_Practice_Guideline_Conflict_of_Interest_Disclosure_Statement.

2. Kazda T, Dziacky A, Burkon P et al. Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: More controversies than standards? Radiol Oncol 2018; 52 (2): 121–128. doi: 10.2478/raon-2018-0023.

3. Kazda T, Lakomý R, Poprach A et al. Multidisciplinární přístup v léčbě gliomů – astrocytomy a oligodendrogliomy. Postgraduální medicína 2020; 22 (2): 137–142.

4. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987–996. doi: 10.1056/NEJMoa043330.

5. Kazda T, Pospíšil P, Šlampa P. Kontroverze při současné radioterapii high-grade gliomů. Postgraduální medicína 2017; 19 (2): 195–200.

6. Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2016; 6 (4): 217–225. doi: 10.1016/j.prro.2016.03.007.

7. Sulman EP, Ismaila N, Armstrong TS et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline. J Clin Oncol 2016; 35 (3): 361–369. doi: 10.1200/JCO.2016.70.7562.

8. Niyazi M, Brada M, Chalmers AJ et al. ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol 2016; 118 (1): 35–42. doi: 10.1016/j.radonc.2015.12.003.

9. Wernicke AG, Smith AW, Taube S et al. Glioblastoma: Radiation treatment margins, how small is large enough? Pract Radiat Oncol 2016; 6 (5): 298–305. doi: 10.1016/j.prro.2015.12.002.

10. Kazda T, Pafundi DH, Kraling A et al. Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas. Phys Imaging Radiat Oncol 2018; 6: 94–100. doi: 10.1016/j.phro.2018.06.004.

11. Law I, Albert NL, Arbizu J et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019; 46 (3): 540–557. doi: 10.1007/s00259-018-4207-9.

12. Ogura K, Mizowaki T, Arakawa Y et al. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: A retrospective cohort study in a single institution. Radiat Oncol 2013; 8 (1): 1–9. doi: 10.1186/1748-717X-8-97.

13. Minniti G, Amelio D, Amichetti M et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97 (3): 377–381. doi: 10.1016/j.radonc.2010.08.020.

14. Chang EL, Akyurek S, Avalos T et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007; 68 (1): 144–150. doi: 10.1016/j.ijrobp.2006.12.009.

15. Kazda T, Hardie JG, Pafundi DH et al. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. J Neurooncol 2015; 122 (1): 197–203. doi: 10.1007/s11060-014-1703-z.

16. Wen PY, Macdonald DR, Reardon D et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11): 1963–1972. doi: 10.1200/JCO.2009.26.3541.

17. Belanova R, Sprlakova-Pukova A, Standara M et al. In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region. [online]. Available from: https: //biomed.papers.upol.cz/search.php?q=Belanova.

18. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131 (6): 803–820. doi: 10.1007/s00401-016-1545-1.

19. Baldock AL, Yagle K, Born DE et al. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro Oncol 2014; 16 (6): 779–786. doi: 10.1093/neuonc/nou027.

20. Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status. J Clin Oncol 2009; 27 (8): 1275–1279. doi: 10.1200/JCO.2008.19.4969.

21. Lim DA, Cha S, Mayo MC et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 2007; 9 (4): 424–429. doi: 10.1215/15228517-2007-023.

22. Scoccianti S, Detti B, Gadda D et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol 2015; 114 (2): 230–238. doi: 10.1016/j.radonc.2015.01.016.